Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3046 - The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients

Date

09 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Non-Small Cell Lung Cancer

Presenters

Laura Mezquita

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

L. Mezquita1, E. Auclin2, M. Charrier3, R. Ferrara1, J. Remon Masip1, D. Planchard1, S. Ponce Aix1, L. Paz-Ares4, J. Lahmar1, L. Leroy5, C. Audigier-Valette6, J. Zeron-Medina Cuairan7, P. Garrido Lopez8, S. Brosseau9, J. Mazieres10, C. CARAMELLA11, J. Adam12, N. Chaput3, J. Soria13, B. Besse1

Author affiliations

  • 1 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Medical Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 3 Laboratory Of Immunomonitoring In Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Medical Oncology Department, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 5 Medical Oncology, Bergonié, 33 - bordeaux/FR
  • 6 Pneumologie, CH Toulon, Toulon/FR
  • 7 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 8 Medical Oncology, Hospital Universitario Ramón y Cajal, 28034 - Madrid/ES
  • 9 Thoracic Oncology Department, Hopital Bichat Claude Bernard, 75018 - Paris/FR
  • 10 Thoracic Oncology Department, Toulouse University Hospital, Toulouse/FR
  • 11 Radiology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 12 Pathology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 13 Department Of Drug Development, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
More

Resources

Abstract 3046

Background

Derived NLR (neutrophils/(leucocytes-neutrophils) ratio) and lactate dehydrogenase (LDH) have been correlated to immune checkpoint inhibitors (ICI) benefit in melanoma. We tested whether baseline dNLR and LDH, as a score, could have the same role in advanced NSCLC patients.

Methods

Baseline dNLR and LDH were retrospectively collected in 466 patients treated with ICI from Nov. 2013 to Jan. 2017, in a training cohort (N = 161) and a validation cohort (N = 305) from 8 European centers. As a control, a cohort (N = 162) treated only with chemotherapy between Nov. 2012 and Jul. 2016 from 2 centers. The primary endpoint was overall survival (OS), and secondary endpoints were progression free survival (PFS) and disease control rate (DCR).

Results

In the immunotherapy cohort, 301 patients (65%) were males, 422 (90%) smokers and 401 (87%) with PS ≤ 1, with median age 63 years; 270 (58%) had adenocarcinoma and 159 (34%) squamous; 85 (18%) were KRASmut, 19 (4%) EGFRmut and 6 (1%) ALK positive. PDL1 was ≥ 1% by immunohistochemistry in 96 (74%), negative in 33 (26%) and unknown in 337 patients. The median of prior lines was 1 (0-11). In the training cohort, the median PFS and OS were 3 months (m) [2-4] and 10m [8-13]. dNLR>3 and LDH> Upper Limit of Normal (ULN) were independent factors for OS (HR 2.22, 95% CI 1.23-4.01; HR 2,51, 1.32-4.76, respectively). According to dNLR>3 and LDH>ULN, LIPI categorized 3 groups (good: 0 factor, intermediate: 1 factor, poor: 2 factors), which correlated with outcome in both cohorts. Median OS for good, intermediate, and poor was 34m, 10m and 3m, respectively (p = 0.0001). The PFS and DCR were also correlated (p = 0.001, p = 0.005). Same results were observed in the validation cohort for OS (p = 0.004), PFS and DCR (both p = 0.005), but not in the chemotherapy cohort for both factors analyzed.

Conclusions

Baseline LIPI, combining dNLR>3 and LDH>ULN, predicts the resistance to ICI acording to OS, PFS and DCR, but it is not correlated with the efficacy of chemotherapy, suggesting LIPI as a predictive score in ICI treatment.

Clinical trial identification

Legal entity responsible for the study

Prof Benjamin Besse

Funding

None

Disclosure

J-C. Soria: Consultancy fees from AstraZeneca, Astex, Clovis, GSK, Gammamabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, Pharmamar, Pierre Fabre, Roche-Genentech, Sanofi, Servier, Symphogen, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.